Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyStar DoseCoach versus routine titration of insulin glargine in adults with type 2 diabetes mellitus
2014-004533-13Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Percentage of patients reaching fasting SMPG target without severe hypoglycemia. Started May 2015; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-004533-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004533-13.